Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD

NCT ID: NCT03392961

Last Updated: 2018-01-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 51 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-27
• Study Completion Date: 2014-07-01

Brief Summary

A study to evaluate the PK and PD of oral IN-105 (Insulin Tregopil) w.r.t. time of dosing prior to meal, duration between meals and type of meal .

Detailed Description

A Phase 1, Randomized, Placebo Controlled, Crossover Trial in Type 2 Diabetes Patients to evaluate the effect of pre-meal dosing time, inter-meal interval and meal composition on the PK and PD of IN-105 (Insulin Tregopil), an oral insulin; conducted in 3 sequential cohorts in an adaptive manner .

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

IN-105 (Insulin Tregopil)

Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.

Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.

Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F).

Group Type: EXPERIMENTAL

IN-105 (Insulin Tregopil)

Intervention Type: DRUG

15 mg strength tablets for oral use used at a dose of 30 mg

Placebo tablet

Cohort1: Treatments A, B, and C: IN-105 administered at 30, 20 or 10 minutes before the ADA meal, respectively; Treatment D: Placebo administered at 20 minutes before the ADA meal.

Cohort 2: Treatments A, B, and C: IN-105 administered at 4, 5, and 6 hours after the previous ADA meal, respectively; Treatments D, E, and F: Placebo administered at 4, 5, and 6 hours after the previous ADA meal, respectively.

Cohort 3: For the first meal, IN-105 30 mg administered at the optimal pre meal time determined from Cohort 1 with ADA meal (Treatments A and D) or high fat meal (Treatments B and E) or high fiber meal (Treatments C or F).

Group Type: PLACEBO_COMPARATOR

Placebo comparator

Intervention Type: OTHER

Placebo tablet for oral use

Interventions

IN-105 (Insulin Tregopil)

15 mg strength tablets for oral use used at a dose of 30 mg

Intervention Type: DRUG

Placebo comparator

Placebo tablet for oral use

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Patient should have an established diagnosis of T2DM per ADA 2013 criteria for at least 1 year prior to screening and are on metformin treatment for at least a month before screening.

2. Body mass index (BMI) of 18.5 to 40.00 kg/m2, both inclusive

3. Glycosylated hemoglobin (HbA1c) ≤ 9.5%.

4. Hemoglobin ≥9.0 g/dL.

5. No clinically significant abnormality in the ECG at screening.

6. Fasting plasma glucose levels less than 140 mg/dL at screening.

7. The patient should be ready to give a written and signed informed consent before starting any protocol-specific procedures.

Exclusion Criteria

1. History of hypersensitivity to insulins or insulin analogues.

2. Evidence of the following (either due to improper diabetes control or due to secondary complications following diabetes).

1. History of ≥2 episodes of severe hypoglycemia within 6 months before screening or history of hypoglycemia unawareness as judged by the investigator.

2. History of ≥1 episodes of hyperglycemic hyperosmolar state or emergency room visits for uncontrolled diabetes leading to hospitalization in the 6 months prior to screening.

3. History of limb amputation as a complication of diabetes during his/her lifetime or any vascular procedure during the 1 year prior to screening.

4. History of diabetic foot or diabetic ulcers in the past 1 year prior to screening.

5. History of severe form of neuropathy or cardiac autonomic neuropathy (determined when obtaining patient history).

3. Presence of any of the following:

1. Serological evidence of human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C infection at screening.

2. Any clinically significant abnormality in the safety laboratory tests conducted at screening.

3. Impaired hepatic function at screening [alanine transaminase (ALT) or aspartate aminotransferase (AST) value >2 times the upper limit of the reference range and/or serum bilirubin 1.5 times the upper limit of the reference range] which investigator considers clinically significant.

4. Evidence of clinically significant chronic renal disease (e.g. nephrotic syndrome, diabetic nephropathy) as assessed by the investigator at screening

4. History or use of the following:

1. Patients on OADs other than metformin for previous three months prior to screening.

2. Patients who have received ≥14 consecutive days of oral, intravenous, or inhaled glucocorticoid therapy within the past 1 year or have received steroids by any route within 4 weeks immediately preceding screening visit (intra-nasal, intra ocular, and topical steroid use is allowed).

5. Receipt of another investigational drug in the 4 weeks prior to screening, or within 5 half-lives of the another investigational drug at screening visit (whichever is longer), or scheduled for another investigational drug during the current study period.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biocon Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Juan Carlos Rondon, M.D,JD

Role: PRINCIPAL_INVESTIGATOR

Elite Research Institute, 15705 NW 13th Avenue, Miami, Florida 33169

References

Khedkar A, Lebovitz H, Fleming A, Cherrington A, Jose V, Athalye SN, Vishweswaramurthy A. Pharmacokinetics and Pharmacodynamics of Insulin Tregopil in Relation to Premeal Dosing Time, Between Meal Interval, and Meal Composition in Patients With Type 2 Diabetes Mellitus. Clin Pharmacol Drug Dev. 2020 Jan;9(1):74-86. doi: 10.1002/cpdd.730. Epub 2019 Aug 7.

Reference Type: DERIVED

PMID: 31392840 (View on PubMed)

Other Identifiers

IN-105-DM-01-G-14

Identifier Type: -

Identifier Source: org_study_id